Loading
A phase 2/3 trial of Piflufolastat F-18 / Pylarify TruVu in Prostate cancer, run by Progenics Pharmaceuticals, Inc., completed.
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer is a phase 2/3 interventional study registered as NCT02981368 by Progenics Pharmaceuticals, Inc., with 385 participants recorded, started 2016-11 and reaching its primary completion in 2018-07. Interventions recorded: 18F-DCFPyL Injection, PET/CT imaging. Conditions recorded: Prostate Cancer.
Linked to the drug Piflufolastat F-18 / Pylarify TruVu because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Piflufolastat F-18 / Pylarify TruVu, Lantheus, Prostate cancer and the tag pipeline.
Shares Piflufolastat F-18 / Pylarify TruVu, Prostate cancer and the tag pipeline.
Shares Lantheus and the tag pipeline.
Shares Lantheus and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.